US009636375B2

(12) **United States Patent**
Wang et al.

(10) **Patent No.: US 9,636,375 B2**
(45) **Date of Patent: *May 2, 2017**

(54) **HEPATITIS C VIRUS INHIBITORS**

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**, Princeton, NJ (US)

(72) Inventors: **Alan Xiangdong Wang**, Wallingford, CT (US); **Li-Qiang Sun**, Glastonbury, CT (US); **Sing-Yuen Sit**, Meriden, CT (US); **Ny Sin**, East Hampton, CT (US); **Paul Michael Scola**, Glastonbury, CT (US); **Yan Chen**, Wallingford, CT (US)

(73) Assignee: **Bristol-Myers Squibb Company**, Princeton, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/936,419**

(22) Filed: **Nov. 9, 2015**

(65) **Prior Publication Data**

US 2016/0067302 A1 Mar. 10, 2016

Related U.S. Application Data

(60) Continuation of application No. 14/477,594, filed on Sep. 4, 2014, now Pat. No. 9,227,940, which is a continuation of application No. 14/183,247, filed on Feb. 18, 2014, now Pat. No. 8,889,871, which is a continuation of application No. 13/091,637, filed on May 24, 2013, now Pat. No. 8,710,229, which is a division of application No. 13/597,381, filed on Aug. 29, 2012, now Pat. No. 8,507,722, which is a

(Continued)

(51) **Int. Cl.**

A61K 31/40	(2006.01)
A61K 38/06	(2006.01)
C07D 207/16	(2006.01)
C07D 401/12	(2006.01)
C07D 401/14	(2006.01)
C07D 403/12	(2006.01)
C07D 413/14	(2006.01)
C07D 417/14	(2006.01)
C07D 491/04	(2006.01)
C07K 5/062	(2006.01)
C07K 5/083	(2006.01)
C07K 5/08	(2006.01)
C07D 217/24	(2006.01)
A61K 45/06	(2006.01)
A61K 38/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/06*** (2013.01); ***A61K 31/40*** (2013.01); ***A61K 38/005*** (2013.01); ***A61K 45/06*** (2013.01); ***C07D 207/16*** (2013.01); ***C07D 217/24*** (2013.01); ***C07D 401/12*** (2013.01); ***C07D 401/14*** (2013.01); ***C07D 403/12*** (2013.01); ***C07D 413/14*** (2013.01); ***C07D 417/14*** (2013.01); ***C07D 491/04*** (2013.01); ***C07K 5/06034*** (2013.01); ***C07K 5/06052*** (2013.01); ***C07K 5/0808*** (2013.01); ***C07K 5/0827*** (2013.01); *A61K 38/00* (2013.01)

(58) **Field of Classification Search**

CPC A61K 38/06; A61K 38/00; A61K 38/005; A61K 31/40; A61K 45/06; C07D 207/16; C07D 401/12; C07D 401/14; C07D 403/12; C07D 413/14; C07D 417/14; C07D 491/04; C07D 217/24; C07K 5/06034; C07K 5/0808; C07K 5/0827; C07K 5/06052

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,223,432 A 6/1993 Wirz et al.
6,878,722 B2 4/2005 Campbell et al.
(Continued)

FOREIGN PATENT DOCUMENTS

WO WO 98/17679 A1 4/1998
WO WO 99/07733 A2 2/1999
(Continued)

OTHER PUBLICATIONS

Lauer, G.M. et al., "Hepatitis C Virus Infection", The New England Journal of Medicine, vol. 345, No. 1, pp. 41-52 (2001).

Llinàs-Brunet, M. et al., "A Systematic Approach to the Optimization of Substrate-Based Inhibitors of the Hepatitis C Virus NS3 Protease: Discovery of Potent and Specific Tripeptide Inhibitors", Journal of Medicinal Chemistry, vol. 47, No. 26, pp. 6584-6594 (2004).

Poupart, M.-A. et al., "Solid-Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease", The Journal of Organic Chemistry, vol. 66, No. 14, pp. 4743-4751 (2001).

(Continued)

Primary Examiner — D M Seaman

(74) *Attorney, Agent, or Firm* — Pamela A. Mingo

(57) **ABSTRACT**

Hepatitis C virus inhibitors are disclosed having the general formula:

(I)



wherein R_1, R_2, R_3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

1 Claim, No Drawings